阿得贝利单抗注射液 | China Drugs ListAdebrelimab injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 上海盛迪医药有限公司Shanghai Shengdi Pharmaceutical Co., Ltd.
- 药品类型
- 生物药Biologic
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 1. 与卡铂和依托泊苷联合，用于广泛期小细胞肺癌患者的一线治疗。 2. 联合含铂化疗作为新辅助治疗，并在手术后继续本品单药辅助治疗，用于可切除的II期、IIIA期或IIIB期、无已知EGFR突变或ALK重排的非小细胞肺癌成人患者。(1) With carboplatin and etoposide as first-line treatment of extensive-stage small cell lung cancer. (2) With platinum-based chemotherapy as neoadjuvant treatment, followed after surgery by adebrelimab monotherapy as adjuvant treatment, for adults with resectable stage II, IIIA or IIIB non-small cell lung cancer without a known EGFR mutation or ALK rearrangement.
- 适应症来源与口径
- 来源日期： 2026-06-23. 生产商面向中国大陆的药品说明书。Source date(s): 2026-06-23. Manufacturer prescribing information for Mainland China.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 2025国家医保目录未匹配；待人工复核Not matched in the 2025 national list; manual review pending
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保核查说明
- 未在提取的目录中匹配到，并不证明被排除。复方制剂仍需人工复核。No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.